Market Analysis and Price Projections for Viberzi
Overview of Viberzi
Viberzi, also known as eluxadoline, is a peripheral opioid receptor mixed agonist/antagonist used primarily for the treatment of irritable bowel syndrome with diarrhea (IBS-D). It is marketed by AbbVie and has been a significant player in the IBS treatment market since its approval.
Market Segmentation and Revenue
The global irritable bowel syndrome treatment market is segmented into various types, including IBS-D and IBS-C. The IBS-D segment, where Viberzi is predominantly used, dominated the market with a revenue share of 49.8% in 2024. This dominance is attributed to the rise in diagnosed cases and an increasing understanding of the condition's impact on quality of life[1][4].
Growth Projections
Viberzi is expected to grow at a Compound Annual Growth Rate (CAGR) of 7.5% over the forecast period, contributing significantly to the growth of the IBS treatment market. This growth is driven by the drug's effectiveness in regulating bowel function and reducing abdominal discomfort, as well as ongoing clinical trials and research aimed at enhancing IBS treatments[1][4].
Competitive Landscape
In the IBS treatment market, Viberzi competes with other notable drugs such as Linzess (linaclotide), Amitiza (lubiprostone), and Xifaxan (rifaximin). Linzess/Constella, for instance, dominated the market with a revenue share of 37.3% in 2024, primarily due to its effectiveness in managing constipation-predominant IBS (IBS-C)[1][4].
Distribution Channels
The distribution of Viberzi is primarily through hospital pharmacies, which accounted for the largest revenue share in 2024. This is due to the comprehensive infrastructure and integrated patient care systems of hospital pharmacies[4].
Regional Market
North America, particularly the U.S., dominates the global IBS treatment market, accounting for the largest revenue share of 37.5% in 2024. This is due to the high prevalence of IBS and increasing awareness of its management options in this region[4].
Pricing and Cost Considerations
The cost of Viberzi is significant, with a supply of 60 tablets (75 mg or 100 mg) costing around $1,696 for cash-paying customers. However, there are savings programs available, such as the Viberzi Savings Program, which allows eligible commercially insured patients to pay $30 per 30-day prescription, with a maximum savings of $10,771 per calendar year[2].
Generic Entry and Patent Exclusivity
Viberzi's patent exclusivity is set to expire on March 14, 2033, which marks the earliest date for potential generic entry. This could significantly impact the pricing and market dynamics of Viberzi, as generic versions often lead to reduced prices and increased competition[5].
Impact of COVID-19
The COVID-19 pandemic has indirectly contributed to the growth of the IBS-D market, including Viberzi, due to increased sedentary lifestyles and changes in dietary habits. These factors have led to a higher incidence of irritable bowel syndrome, thereby increasing the demand for effective treatments like Viberzi[3].
Key Takeaways
- Market Dominance: Viberzi is a leading treatment for IBS-D, with a significant market share driven by its effectiveness.
- Growth Projections: Expected to grow at a CAGR of 7.5% over the forecast period.
- Pricing: High cost for cash-paying customers, but savings programs are available.
- Generic Entry: Patent exclusivity expires in 2033, which could impact pricing and market competition.
- Regional Focus: North America, particularly the U.S., is a major market for Viberzi.
FAQs
Q: What is Viberzi used for?
A: Viberzi (eluxadoline) is used for the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Q: How much does Viberzi cost?
A: The cost for a supply of 60 tablets of Viberzi is around $1,696 for cash-paying customers, but savings programs can reduce this cost.
Q: What is the expected growth rate of Viberzi in the market?
A: Viberzi is expected to grow at a CAGR of 7.5% over the forecast period.
Q: When will generic versions of Viberzi be available?
A: The earliest date for generic entry is March 14, 2033, based on current patent exclusivity.
Q: How has the COVID-19 pandemic affected the demand for Viberzi?
A: The pandemic has led to increased sedentary lifestyles and dietary changes, resulting in a higher incidence of IBS-D and thus increasing the demand for Viberzi.
Sources
- Grand View Research: Irritable Bowel Syndrome Treatment Market Size Report 2030.
- Drugs.com: Viberzi Prices, Coupons, Copay Cards & Patient Assistance.
- Business Wire: Insights on the Irritable Bowel Syndrome with Diarrhea Global Market to 2028.
- ResearchAndMarkets: Irritable Bowel Syndrome Treatment Market Size & Competitors.
- DrugPatentWatch: When do the VIBERZI patents expire, and when will generic versions be available?
